Le Lézard
Classified in: Health
Subject: VET

R3 Stem Cell Heroes Program Performs Complimentary Regenerative Therapies on 70 Veterans in 2019


LAS VEGAS, Feb. 20, 2020 /PRNewswire-PRWeb/ -- R3 Stem Cell, the nation's leader in regenerative therapies and provider training, announced that its Heroes Program was able to complete 70 complimentary stem cell procedures on military veterans in 2019. The veterans traveled from all over the US to receive the regenerative therapies at no cost.

At the R3 Stem Cell Training Course for doctors, providers of all kinds learn how to perform regenerative procedures in a supervised setting. This includes stem cell and exosome procedures on military veterans of all ages and from all branches of service. Any veteran can be nominated (or nominate themselves), and the pain being experienced does not have to be a result of a service related injury.

According to R3 Stem Cell CEO David Greene, MD, MBA, "When we hear the stories of these Veterans and what they have done for America, it's so exciting to be able to do something to help improve their quality of life. Especially Veterans of the Vietnam War, all they wanted to do was protect our country. To see how well they do afterwards and then refer in their Veteran friends for procedures, it's amazing!"

The chosen Veterans receive an evaluation by the Board Certified doctors who are trainers, and then procedures include whatever amount of regenerative biologic deemed appropriate. The Veteran patients are followed up the R3 staff, and invited back for additional therapies when necessary.

To date over 70 Veterans have successfully receive regenerative therapies in the program. Over a dozen patients are treated at each workshop, with more opportunities upcoming. Added Dr. Greene, "Our stem cell courses are extremely hands on an providers love it. They have been increasing in popularity continuously, which allows us to treat more Veterans!"

For those who would like to nominate a Veteran for the Heroes Program to receive free stem cell therapy, simply visit https://r3stemcell.com/hero or call (844) GET-STEM.

 

SOURCE R3 Stem Cell


These press releases may also interest you

at 07:08
Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease
Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce the successful initiation and first two patients enrollment for its global multicenter...

at 07:05
Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin
Bruker Corporation is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second quarter of 2024. This ultra-high field NMR...

at 07:05
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge® Infusion System in Japan
KORU Medical Systems, Inc. ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today...

at 07:05
Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy ("DMD")
Satellos Bioscience Inc. ("Satellos" or the "Company") , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced preliminary results from a single case...

at 07:00
ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant to Advance GPR35 Inhibitor Program with Initial Focus on Inflammatory Gastrointestinal Disease Ulcerative Colitis
ThirtyFiveBio Limited,...

at 07:00
DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency
DRI Healthcare Trust (the "Trust"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a second royalty interest in the worldwide net sales of Xenpozyme (olipudase alfa) from HLS...

More news about Health...


News published on and distributed by: